Pre Refunding Definition & Meaning | Financial Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Pre Refunding

Financial Term

Pre-refunding is a financial term used to describe the process of issuing a new bond or security to pay off an existing bond before its maturity date. The existing bonds, often referred to as the callable bonds, typically carry higher interest rates compared to the current market rates. Hence, issuers have an opportunity to refinance them at lower costs by issuing new bonds. Pre-refunding allows issuers to lock-in lower rates and save money on interest payments, while providing investors with a guaranteed source of income.

Pre-refunding is a common strategy used in the financial industry to reduce borrowing costs. Companies, municipalities, and government institutions that have issued callable bonds can use this strategy to save money when interest rates are low. Pre-refunding can also help to improve credit ratings as it reflects the issuer*s ability and willingness to manage its debt and leverage its finances. Additionally, pre-refunding can provide a source of liquidity to issuers, which can be important for sustaining operations, especially during challenging economic times.

Overall, pre-refunding is a valuable tool for issuers to manage debt, reduce borrowing costs, and enhance their financial well-being. It is a powerful financial strategy that requires careful analysis, planning, and execution to maximize its benefits.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P